Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU Pharmacovigilance Fees Could Cripple Drug Firms, Says Pharma Industry

This article was originally published in The Pink Sheet Daily

Executive Summary

Fees set to be introduced to cover the cost of the European Medicines Agency’s part in improving drug safety could impose a huge burden on the EU pharmaceutical industry and lead to the closure of smaller firms, the industry says.

You may also be interested in...



OTC Firms Could Gain From Proposed EU Risk Management Plan Revision

AESGP and EFPIA are set to submit a joint proposal to the EMA that would streamline risk management plans for long-marketed products and provide uniform treatment for products approved under differing regulatory procedures.

OTC Firms Could Gain From Proposed EU Risk Management Plan Revision

AESGP and EFPIA are set to submit a joint proposal to the EMA that would streamline risk management plans for long-marketed products and provide uniform treatment for products approved under differing regulatory procedures.

EU Risk Plan Easing For Long-Marketed Products Sought By Industry Groups

EFPIA and AESGP are set to submit a joint proposal to the EMA that would streamline risk management plans for long-marketed products and provide uniform treatment for products approved under differing regulatory procedures.

Related Content

Topics

UsernamePublicRestriction

Register

ID034708

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel